Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/anxiolytic response

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 3, 2004, Pages 208-218

  Blier, Pierre ^a   Gobbi, Gabriella ^b   Haddjeri, Nasser ^c   Santarelli, Luca ^d   Mathew, Gina ^e   Hen, René ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ LYON 1   (France)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antidepressive agents; Depression; Norepinephrine; Receptors, adrenergic; Receptors, neurokinin 1; Serotonin; Substance P

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 [[2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 MORPHOLINYL]METHYL] N,N DIMETHYL 1H 1,2,3 TRIAZOLE 4 METHANAMINE; APREPITANT; CLONIDINE; MIRTAZAPINE; NORADRENALIN; RP 68750; SEROTONIN; SUBSTANCE P ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; TETRODOTOXIN; UNCLASSIFIED DRUG; VOFOPITANT;

ANXIETY; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONFERENCE PAPER; DORSAL RAPHE NUCLEUS; DRUG EFFECT; ELECTROPHYSIOLOGY; FOREBRAIN; GENE DELETION; HIPPOCAMPUS; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; MICRODIALYSIS; MICROIONTOPHORESIS; MUTANT; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PRESYNAPTIC INHIBITION; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; TIMED DRUG RELEASE; TRANQUILIZING ACTIVITY;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTIEMETICS; ANXIETY; AUTORECEPTORS; DEPRESSIVE DISORDER, MAJOR; ELECTROPHYSIOLOGY; HIPPOCAMPUS; LOCUS COERULEUS; MICE; MICE, MUTANT STRAINS; MORPHOLINES; NOREPINEPHRINE; PHENYLEPHRINE; PHOTOMICROGRAPHY; RAPHE NUCLEI; RECEPTORS, NEUROKININ-1; SEROTONIN; SUBSTANCE P;

EID: 3042611638     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
2. Thase ME, Ninan PT. New goals in the treatment of depression: moving toward recovery. Psychopharmacol Bull 2002;36(Suppl 2):24-35.
3. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-5.
4. Guyenet PG, Aghajanian GK. Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides. Brain Res 1977;136:178-84.
5. McLean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, et al. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 1991;251:437-9.
6. Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 1999;10:3967-70.
7. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996;739:70-8.
8. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 2001;922:9-20.
9. Chen LW, Wei LC, Liu HL, Rao ZR. Noradrenergic neurons expressing substance P receptor (NK1) in the locus coeruleus complex: a double immunofluoresence study in the rat. Brain Res 2000;873:155-9.
10. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A 2001;98:1912-7.
11. Liu R, Ding Y, Aghajanian GK. Neurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. Neuropsychopharmacology 2002;27:329-40.
12. Haddjeri N, Blier P. Effect of neurokinin-1 receptor antagonists on the function of 5-HT and noradrenaline neurons. Neuroreport 2000;11:1323-7.
13. Haddjeri N, Blier P. Effects of neurokinin 1 antagonists on the firing of locus coeruleus norepinephrine neurons. Abstr Soc Neurosci 2001;31:749.
14. Maubach KA, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain CJ, et al. Chronic substance P (NK1) receptor antagonist and convention: antidepressant treatment increases burst firing of monoamine neurons in the locus coeruleus. Neuroscience 2002;109:609-17.
15. Gobbi G, Santarelli L, Hen R, Blier P. Neurokinin 1 (NK1), serotonin (5-HT) and norepinephrine (NE) receptors interactions: in vivo electrophysiological evidence. Abstr Soc Neurosci 2001;31:239.
16. Bert L, Rodier D, Bougault I, Allouard N, Le Fur G, Soubrie P, et al. Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142801. Synapse 2002;43:62-9.
17. Millan MJ, Lejeune F, De Nanteuil G, Gobert A. Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 2001;76:1949-54.
18. Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 1975;92:291-306.
19. 1A autoreceptor in vivo in the rat brain. Abstr Soc Neurosci 2001;31:124.
20. Wang RY, Aghajanian GK. Physiological evidence for habenula as major link between forebrain and midbrain raphe. Science 1977;197:89-91.
21. Nishikawa T, Fage D, Scatton B. Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res 1986;373:324-36.
22. Conley RK, Cumberbatch MJ, Mason GS, Williamson DJ, Harrison T, Locker K, et al. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 2002;22:7730-6.
23. Froger N, Gardier AM, Mratalla R, Alberti I, Lena I, Boni C, et al. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 2001;21:8188-97.
24. 1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone. J Pharmacol Exp Ther 1993;265:7-15.
25. 1B receptor knockout mice. J Neurochem 2003;86:13-24.
26. Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 2001;50:191-9.
27. 1A receptors. Eur J Pharmacol 2002;435:195-203.
28. Haddjeri N, Szabo ST, de Montigny C, Blier P. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology 2000;22:346-56.
29. 3H]-serotonin release in rat hypothalamic slices. Naunyn Schmiedebergs Arch Pharmacol 1989;339:60-4.
30. Gonon FG. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 1988;24:19-28.
31. Gartside SE, Hajos-Korcsok E, Bagdy E, Harsing LG Jr, Sharp T, Hajos M. Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 2000;98:295-300.
32. Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 2001;50:510-20.
33. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999;21(2 Suppl): 91S-98S.
34. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazepine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1966;277:861-71.
35. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine neuron firing by sustained bupropion treatment. Psychopharmacology 2001;155:52-7.
36. Bondy B, Baghai B, Minov C, Schule C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003;15;53:538-42.
37. Stockmeier CA, Shi X, Konick L, Overholser JC, Jurjus G, Meltzer HY, et al. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport 2002;12:1223-7.
38. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-28.
39. Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, et al. Tryptophan depletion and depressive vulnerability. Biol Psychiatry 1999;46:498-505.